Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2007

View Archived Issues

BioGeneriX and Neose extend GlycoPEG-GCSF collaboration

NovaDel raises funds to advance oral spray drug candidates

Thalidomide to be evaluated for the treatment of MIA syndrome in dialysis patients / News in Context

Grazax launched in U.K., Denmark and Norway

FDA approval for generic Atenolol Tablets

Shandong Luye acquires cancer drug CMNa

Exelixis and Genentech sign agreement for MEK inhibitor XL-518

4SC and XL TechGroup form new company to develop biofilm inhibitors

Grifols receives FDA approval for new generation of IVIG

Zydus launches Simvastatin Tablets

Perrigo receives FDA approval for Ciclopirox Topical Suspension

REG1 anticoagulant system safe in humans

VGX-1027 active against diabetes in preclinical models

PRO-132365 investigated in breast cancer trial

E75 vaccine safe and active in high-risk breast cancer

Novel monoamine reuptake inhibitors emerge from NeuroSearch R&D

Novel antibacterial agents patented

New CCR-5 receptor modulators prepared and tested at Kemia

Higher recovery rate after stroke for DP-b99-treated patients

Transdur-Bupivacaine begins phase II for postherpetic neuralgia

Phase II program under way for TD-1792 in Gram-positive cSSSI

SPA agreement for pivotal phase III study of picoplatin in SCLC

U.K. clearance for clinical study of Reolysin with docetaxel in advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...